EUVIMEDEUVIMED entdecken
Fallbericht

A case of systemic lupus erythematosus complicated by TAFRO syndrome-like conditions: analysis of C–X–C motif chemokine ligand 13 and B-cell activating factor dynamics and the efficacy of combination therapy with cyclosporine and belimumab

Shotaro Suzuki iD, Yukiko Takakuwa iD, Yoshiki Ishizaki, Tatsuya Kawasaki, Seido Ooka iD, Kimito Kawahata iD

Modern Rheumatology Case Reports · 2025

DOI: 10.1093/mrcr/rxaf063 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, 2025. Verfasst von Shotaro Suzuki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Allergology, St Marianna University School of Medicine, Kanagawa, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, B-Cell Activating Factor, Cyclosporine, Lupus Erythematosus, Systemic. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TAFRO syndrome, characterised by thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly, is a rare subtype of idiopathic multicentric Castleman disease. Although it is generally not associated with autoimmune diseases, cases with systemic lupus erythematosus have been reported. We report a case of a 52-year-old male with systemic lupus erythematosus complicated by TAFRO syndrome-like conditions. The patient had persistent thrombocytopenia, renal dysfunction, and fluid retention refractory to glucocorticoids, IL-6 inhibitors, and plasma exchange. Treatment with cyclosporine and belimumab was initiated due to a suspicion of aberrant B-cell activation, resulting in a 2-year remission without relapse. To explore the immunological pathogenesis, CXCL13 and BAFF levels were analysed during the clinical course. Despite interleukin-6 (IL-6) inhibitor therapy, C–X–C motif chemokine ligand 13 (CXCL13) levels remained elevated, suggesting the involvement of an alternative regulatory pathway. Both CXCL13 and B-cell activating factor (BAFF) levels decreased after treatment with cyclosporine and belimumab, and this correlated with clinical improvement. CXCL13, which is produced by peripheral helper T cells, promotes aberrant B-cell activation and lymphoid tissue formation. Meanwhile, BAFF supports B-cell survival and autoreactivity, acting alongside CXCL13 to sustain pathological B-cell activity. This case highlights the importance of therapies targeting T-cell and B-cell interactions in certain diseases with refractory conditions. Additionally, monitoring CXCL13 and BAFF may help optimise therapeutic strategies. Combination therapy with cyclosporine and belimumab effectively suppressed both cytokines, achieving sustained disease control. Future studies should utilise cytokine profiling, including CXCL13 and BAFF, to establish personalised therapeutic strategies in cases of systemic lupus erythematosus presenting with TAFRO syndrome-like conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedB-Cell Activating FactorCyclosporineLupus Erythematosus, SystemicChemokine CXCL13Castleman DiseaseHumansMaleMiddle AgedDrug Therapy, CombinationImmunosuppressive AgentsTreatment Outcome

Stichwörter der Autor:innen

Systemic lupus erythematosusTAFRO syndromebelimumabcyclosporin

Substanzen

belimumabAntibodies, Monoclonal, HumanizedB-Cell Activating FactorCyclosporineChemokine CXCL13Immunosuppressive AgentsTNFSF13B protein, humanCXCL13 protein, human

Autor:innen und Institutionen

  • Department of Rheumatology and Allergology, St Marianna University School of Medicine, Kanagawa, Japan.

ORCID-Profile: Shotaro Suzuki, Yukiko Takakuwa, Seido Ooka, Kimito Kawahata

Zitieren

APA

Suzuki, S., Takakuwa, Y., Ishizaki, Y., Kawasaki, T., Ooka, S., & Kawahata, K. (2025). A case of systemic lupus erythematosus complicated by TAFRO syndrome-like conditions: analysis of C–X–C motif chemokine ligand 13 and B-cell activating factor dynamics and the efficacy of combination therapy with cyclosporine and belimumab. Modern Rheumatology Case Reports. https://doi.org/10.1093/mrcr/rxaf063

Vancouver

Suzuki S, Takakuwa Y, Ishizaki Y, Kawasaki T, Ooka S, Kawahata K. A case of systemic lupus erythematosus complicated by TAFRO syndrome-like conditions: analysis of C–X–C motif chemokine ligand 13 and B-cell activating factor dynamics and the efficacy of combination therapy with cyclosporine and belimumab. Modern Rheumatology Case Reports. 2025. doi:10.1093/mrcr/rxaf063

BibTeX
@article{Suzuki2025,
  author = {Suzuki, Shotaro and Takakuwa, Yukiko and Ishizaki, Yoshiki and Kawasaki, Tatsuya and Ooka, Seido and Kawahata, Kimito},
  title = {A case of systemic lupus erythematosus complicated by TAFRO syndrome-like conditions: analysis of C–X–C motif chemokine ligand 13 and B-cell activating factor dynamics and the efficacy of combination therapy with cyclosporine and belimumab},
  journal = {Modern Rheumatology Case Reports},
  year = {2025},
  doi = {10.1093/mrcr/rxaf063}
}
Kostenlos starten →